Covalent inhibitors in drug discovery: From accidental discoveries to avoided liabilities and designed therapies

Drug Discovery Today

Volumn 20, Issue 9, 2015, Pages 1061-1073

  Bauer, Renato A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BROMOBENZENE; CANERTINIB; DACOMITINIB; DRUG METABOLITE; METHIONYL AMINOPEPTIDASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; N (2 FLUORENYL)ACETAMIDE; NERATINIB; OSIMERTINIB; PARACETAMOL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; ROCILETINIB; STEROID 5ALPHA REDUCTASE; TRANSCRIPTION FACTOR NRF2; TRIACYLGLYCEROL LIPASE; DRUG;

BINDING SITE; CELL PROTECTION; COVALENT BOND; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; HUMAN; IC50; ONCOLOGY; PHARMACODYNAMICS; PHARMACOKINETICS; PROTEIN INTERACTION; PULMONARY HYPERTENSION; REVIEW; DRUG DESIGN; DRUG RESISTANCE; MOLECULARLY TARGETED THERAPY; PROCEDURES;

DRUG APPROVAL; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE; HUMANS; MOLECULAR TARGETED THERAPY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84941022783     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.05.005     Document Type: Review

References (90)

1. 50 values J. Biomol. Screen. 14 2009 913 923
2. M.C. Noe, and A.M. Gilbert Targeted covalent enzyme inhibitors Annu. Rep. Med. Chem. 47 2012 413 439
3. J.G. Robertson Mechanistic basis of enzyme-targeted drugs Biochemistry 44 2005 5561 5571
4. J. Singh, and et al. The resurgence of covalent drugs Nat. Rev. Drug Discov. 10 2011 307 317
5. M.H. Potashman, and M.E. Duggan Covalent modifiers: an orthogonal approach to drug design J. Med. Chem. 52 2009 1231 1246
6. D.S. Johnson, and et al. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors Future Med. Chem. 2 2010 949 964
7. A.S. Kalgutkar, and D.K. Dalvie Drug discovery for a new generation of covalent drugs Expert Opin. Drug Discov. 7 2012 561 581
8. M.H. Johansson Reversible Michael additions: covalent inhibitors and prodrugs Mini-Rev. Med. Chem. 12 2012 1330 1344
9. A.J. Wilson, and et al. Keap calm, and carry on covalently J. Med. Chem. 56 2013 7463 7476
10. R. Mah Drug discovery considerations in the development of covalent inhibitors Bioorg. Med. Chem. Lett. 24 2014 33 39
11. G.J. Roth, and et al. Acetylation of prostaglandin synthase by aspirin Proc. Natl. Acad. Sci. U. S. A. 72 1975 3073 3076
12. P.M. Wright, and et al. The evolving role of chemical synthesis in antibacterial drug discovery Angew. Chem. Int. Ed. 53 2014 8840 8869
13. L. Olbe, and et al. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole Nat. Rev. Drug Discov. 2 2003 132 139
14. P. Savi, and et al. Identification and biological activity of the active metabolite of clopidogrel Thromb. Haemostasis 84 2000 891 896
15. C. Drahl, and et al. Protein-reactive natural products Angew. Chem. Int. Ed. 44 2005 5788 5809
16. B. Huggett Biotech's wellspring: the health of private biotech in 2012 Nat. Biotechnol. 31 2013 396 404
17. K. Garber Principia biopharma Nat. Biotechnol. 31 2013 377
18. L. Guterman Covalent drugs form long-lived ties Chem. Eng. News 89 2011 19 26
19. J.A. Miller The metabolism of xenobiotics to reactive electrophiles in chemical carcinogenesis and mutagenesis: a collaboration with Elizabeth Cavert Miller and our associates Drug Metab. Rev. 30 1998 645 674
20. D.J. Jollow, and et al. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo J. Pharmacol. Exp. Ther. 187 1973 195 202
21. D. Gunnell, and et al. Use of paracetamol (acetaminophen) for suicide and nonfatal poisoning: worldwide patterns of use and misuse Suicide Life-Threat. 30 2010 313 326
22. Y.M. Koen, and R.P. Hanzlik Identification of seven proteins in the endoplasmic reticulum as targets for reactive metabolites of bromobenzene Chem. Res. Toxicol. 15 2002 699 706
23. I.S. Dunn, and et al. Contact sensitivity to urushiol: role of covalent bond formation Cell. Immunol. 74 1982 220 233
24. I.M. Baird, and et al. Repeated dose study of sucralose tolerance in human subjects Food Chem. Toxicol. 38 Suppl. 2 2000 S123 S129
25. V.R. Thompson, and A.P. DeCaprio Covalent adduction of nitrogen mustards to model protein nucleophiles Chem. Res. Toxicol. 26 2013 1263 1271
26. S. Nakayama, and et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding Drug Metab. Dispos. 37 2009 1970 1977
27. J.C.L. Erve Chemical toxicology: reactive intermediates and their role in pharmacology and toxicology Expert Opin. Metab. Toxicol. 2 2006 923 946
28. J.L. Walgren, and et al. Role of metabolism in drug-induced idiosyncratic hepatotoxicity Crit. Rev. Toxicol. 35 2005 325 361
29. C. Lammert, and et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals Hepatology 47 2008 2003 2009
30. J.P. Uetrecht New concepts in immunology relevant to idiosyncratic drug reactions. The 'danger hypothesis' and innate immune system Chem. Res. Toxicol. 12 1999 387 395
31. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 715
32. J. Knowles, and G. Gromo A guide to drug discovery: target selection in drug discovery Nat. Rev. Drug Discov. 2 2003 63 69
33. D.C. Swinney Biochemical mechanisms of drug action: what does it take for success? Nat. Rev. Drug Discov. 3 2004 801 808
34. D.C. Swinney Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001-2004 Curr. Top. Med. Chem. 6 2006 461 478
35. T. Barf, and A. Kaptein Irreversible kinase inhibitors: balancing the benefits and risks J. Med. Chem. 55 2012 6243 6262
36. I.D. Kuntz, and et al. The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 96 1999 9997 10002
37. A.J.T. Smith, and et al. Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins J. Med. Chem. 52 2009 225 233
38. R.J. Polinsky Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease Clin. Ther. 20 1998 634 647
39. A.J. Claxton, and et al. A systematic review of the associations between dose regimens and medication compliance Clin. Ther. 23 2001 1296 1310
40. M.F. Moghaddam, and et al. A proposed screening paradigm for discovery of covalent inhibitor drugs Drug Metab. Lett. 8 2014 19 30
41. C-H. Yun, and et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc. Natl. Acad. Sci. U. S. A. 105 2008 2070 2075
42. Q. Liu, and et al. Developing irreversible inhibitors of the protein kinase cysteinome Chem. Biol. 20 2013 146 159
43. C.R. Chong, and P.A. Jänne The quest to overcome resistance to EGFR-targeted therapies in cancer Nat. Med. 19 2013 1389 1400
44. C.F. Shuman, and et al. Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants Antiviral Res. 58 2003 235 242
45. M. Hagel, and et al. Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine Nat. Chem. Biol. 7 2011 22 24
46. T.A. Halgren Identifying and characterizing binding sites and assessing druggability J. Chem. Inf. Model. 49 2009 377 389
47. L.M. Jarvis The year in new drugs Chem. Eng. News 92 2014 10 13
48. I. Vivanco, and et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors Cancer Discov. 2 2012 459 471
49. P.A. Schwartz, and et al. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance Proc. Natl. Acad. Sci. U. S. A. 111 2014 173 178
50. N. Minkovsky, and A. Berezov BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors Curr. Opin. Investig. Drugs 9 2008 1336 1346
51. S-H.I. Ou Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence Crit. Rev. Oncol. Hematol. 83 2012 47 421
52. J.A. Burger Bruton's tyrosine kinase (BTK) inhibitors in clinical trials Curr. Hematol. Malig. Rep. 9 2014 44 49
53. L.A. Honigberg, and et al. The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U. S. A. 107 2010 13075 13080
54. A. Akinleye, and et al. Ibrutinib and novel BTK inhibitors in clinical development J. Hemat. Oncol. 6 2013 59 67
55. Y. Zhao, and A.A. Adjei The clinical development of MEK inhibitors Nat. Rev. Clin. Oncol. 11 2014 385 400
56. Y. Shen, and et al. Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III Bioorg. Med. Chem. Lett. 20 2010 3155 3157
57. V. Sangwan, and A.K. Saluja Mechanism of action of the anti-cancer agent, Triptolide F.H. Sarkar, Nutraceuticals and Cancer 2012 Springer 135 150
58. C. McCallum, and et al. Triptolide binds covalently to a 90 kDa nuclear protein. Role of epoxides in binding and activity Immunobiology 212 2007 549 556
59. N.T. Ihle, and et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Mol. Cancer Ther. 3 2004 763 772
60. A.F. Kisselev, and et al. Proteasome inhibitors: an expanding army attacking a unique target Chem. Biol. 19 2012 99 115
61. J. Adams Development of the proteasome inhibitor PS-341 Oncologist 7 2002 9 16
62. R.A. Linker, and et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway Brain 134 2011 678 692
63. T.G. Davies, and et al. Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO PLoS ONE 9 2014 98896
64. M. Burg, and N. Green Effect of ethacrynic acid on the thick ascending limp of Henle's loop Kidney Intl. 4 1973 301 308
65. J.H.T.M. Ploemen, and et al. Reversible conjugation of ethacrynic acid with glutathione and human glutathione S-transferase P 1-1 Cancer Res. 54 1994 915 919
66. J.C. Somberg, and J. Molnar The pleiotropic effects of ethacrynic acid Am. J. Ther. 16 2009 102 104
67. D.E. Ehmann, and et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor Proc. Natl. Acad. Sci. U. S. A. 109 2012 11663 11668
68. A.A. Joharapurkar, and et al. Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity Diabetes Metab. Syndr. Obes. Target Ther. 7 2014 73 84
69. T.E. Hughes, and et al. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women Obesity 21 2013 1782 1788
70. R. Guerciolini Mode of action of orlistat Int. J. Relat. Metab. Disord. 21 1997 S12 S23
71. D.S. Johnson, and et al. Discovery of PF-04457845: a highly potent, orally bioavailable, and selective urea FAAH inhibitor ACS Med. Chem. Lett. 2 2011 91 96
72. K. Ahn, and et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain J. Pharmacol. Exp. Ther. 338 2011 114 124
73. M.W. Jann Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease Pharmacotherapy 20 2000 1 12
74. H.G. Bull, and et al. Mechanism-based inhibition of human steroid 5α-reductase by finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor J. Am. Chem. Soc. 118 1996 2359 2365
75. F.G. Njoroge, and et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection Acc. Chem. Res. 41 2007 50 59
76. A. Barnett DPP-4 inhibitors and their potential role in the management of type 2 diabetes Int. J. Clin. Pract. 60 2006 1454 1470
77. A.G. Costa, and et al. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis Nat. Rev. Rheumatol. 7 2011 447 456
78. J.Y. Gauthier, and et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K Bioorg. Med. Chem. Lett. 18 2008 923 928
79. R.D. Couch, and et al. Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action Biorg. Med. Chem. Lett. 15 2005 2215 2219
80. A. Chandrasekaran, and et al. Reversible covalent binding of neratinib to human serum albumin in vitro Drug Metab. Lett. 4 2010 220 227
81. I.M. Serafimova, and et al. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles Nat. Chem. Biol. 8 2012 471 476
82. R.A. Bauer, and et al. Biomimetic diversity-oriented synthesis of benzannulated medium rings via ring expansion Nat. Chem. Biol. 9 2013 21 29
83. J. Gan, and et al. In vitro screening of 50 highly prescribed drugs for thiol adduct formation. Comparison of potential for drug-induced toxicity and extent of adduct formation Chem. Res. Toxicol. 22 2009 690 698
84. A.F. Stepan, and et al. Structural alert/reactive metabolite concept as applied in Medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 24 2011 1345 1410
85. E. Weerapana, and et al. Disparate proteome reactivity profiles of carbon electrophiles Nat. Chem. Biol. 4 2008 405 407
86. S.G. Kathman, and et al. A fragment-based method to discover irreversible covalent inhibitors of cysteine proteases J. Med. Chem. 57 2014 4969 4974
87. C. Jöst, and et al. Promiscuity and selectivity in covalent enzyme inhibition: a systematic study of electrophilic fragments J. Med. Chem. 57 2014 7590 7599
88. R.H. Mann, and et al. Kinetic template-guided tethering of fragments ChemMedChem 2012 2012 2082 2086
89. R.M. Miller, and et al. Electrophilic fragment-based design of reversible covalent kinase inhibitors J. Am. Chem. Soc. 135 2013 5298 5301
90. S.K. Olsen, and et al. Active site remodeling accompanies thioester bond formation in the SUMO E1 Nature 463 2010 906 914